Home » Stocks » Genetic Technologies

Genetic Technologies Ltd. (GENE)

Stock Price: $3.38 USD -0.02 (-0.59%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $3.39 +0.01 (0.30%) Oct 23, 6:36 PM

Stock Price Chart

Key Info

Market Cap 46.54M
Revenue (ttm) 6,803
Net Income (ttm) -6.10M
Shares Out 13.77M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $3.38
Previous Close $3.40
Change ($) -0.02
Change (%) -0.59%
Day's Open 3.39
Day's Range 3.31 - 3.43
Day's Volume 231,396
52-Week Range 1.41 - 10.30

More Stats

Market Cap 46.54M
Enterprise Value 37.74M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.77M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.30
FCF / Share -0.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 145,642
Short Ratio 0.12
Short % of Float n/a
Beta 1.26
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6,841.50
PB Ratio 5.06
Revenue 6,803
Operating Income -5.11M
Net Income -6.10M
Free Cash Flow -3.94M
Net Cash 8.80M
Net Cash / Share 0.64
Gross Margin -2,449.79%
Operating Margin -75,173.12%
Profit Margin -61,830.20%
FCF Margin -57,919.69%
ROA -43.32%
ROE -82.49%
ROIC -1,085.90%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $3.38
Target: 25.65
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial numbers in millions AUD.

Financial Overview

Revenue Growth-61.23%-86.56%-63.5%-53.92%-62.98%-44.01%-33.5%19.55%-63.05%-
Gross Profit-0.24-0.25-
Operating Income-7.42-7.02-6.40-8.72-8.92-9.87-10.21-9.33-10.411.25
Net Income-6.10-6.43-5.46-8.40-8.46-8.81-10.13-9.35-5.300.90
Shares Outstanding4,1552,6352,4352,12242926814411820.2320.23
Earnings Per Share-0.02-0.04-0.03-0.06-0.29-0.49-1.06-1.18-3.450.66
Operating Cash Flow-5.71-6.07-5.64-6.85-7.73-9.69-10.99-7.52-7.672.23
Capital Expenditures--0.05--0.18-0.30-0.14-0.05-0.05-0.040.01
Free Cash Flow-5.71-6.12-5.64-7.03-8.02-9.83-11.04-7.57-7.722.24
Cash & Equivalents14.212.135.4910.9911.1818.342.831.728.905.10
Total Debt1.46-------0.020.07
Net Cash / Debt12.762.135.4910.9911.1818.342.831.728.885.04
Book Value13.021.774.7110.5811.8818.961.835.6414.256.61
Numbers in millions AUD, except per-share numbers.

Company Profile

Company Details

Full Name Genetic Technologies Ltd.
CEO Jerzy Muchnicki

Stock Information

Ticker Symbol GENE
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: GENE


Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.